VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$2.30 USD
+0.10 (4.55%)
Updated Jun 14, 2024 03:59 PM ET
After-Market: $2.31 +0.01 (0.43%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum F VGM
Brokerage Reports
VYNE Therapeutics Inc. [VYNE]
Reports for Purchase
Showing records 21 - 34 ( 34 total )
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Recent Clinical Progress Prepares the Ground for an Active Pipeline in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
FMX114 Starts to Bloom With Additional Positive Phase 1b Data; Phase 2a Results Expected in 2Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYN201 Gains the Upper Hand in Rheumatoid Arthritis Model
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYN201 Ripens on the VYNE with Positive Preclinical Data in Vitiligo
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
FMX114''s Topical Formulation Begins to Bear Fruit; Key Data This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Continues to Turn Over a New Leaf with Sale of MST Franchise
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Powerful Reset in Execution Mode; Inflammation''s New Enemies; Assuming Coverage at Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Exiting Commercial Biz to Focus on New Early-Stage Immuno- Inflammatory Assets; Move to Neutral While Awaiting Clarity
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Slower Volume and Coverage Ramp, But Still See Strong Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q20: Building Commercial Foundation for 2021 Acceleration, While Expanding the Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q20: Rx Trends Strong; Pushing Back Full Realized Value Rx in 2021, but Long-Term Projections Intact; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Raising Zilxi Peak Estimates on Strong KOL Expectations; Increase Target to $3.50, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Bolstered Balance Sheet Provides Runway Through 2022 Break-Even; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O